New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
TREMFYA® , the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease activity and severity through substantial reduction in Sjögren's-related autoantibodies
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
TREMFYA® is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
80 Mile PLC Secures 3 Strategic MOUs with Fortune 500 Energy Group, Ludoil, and JEnergy and moves to 100% of Ferrandina Biofuels Plant
Cotec Purchases Commercial Scale Salter Cyclone Multi-Gravity-Separator Unit to be Located at Corem Québec, Canada
TSX-V: TT Closes Acquisition of High Lake and West Hawk Lake from McFarlane Lake Mining and Closing of Final Tranche of Non-Brokered Private Placement
Element One Hydrogen and Critical Minerals Announces Letter of Intent to Acquire Hydrogen and Critical Mineral Extraction Technology
